The UK and US have announced a landmark trade agreement that will preserve zero tariffs on UK pharmaceutical shipments being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to boost funding on pharmaceuticals through the public health system. This move guarantees that import taxes on these vital products will remain at zero for a timeframe of the next three years.
This development comes after previous warnings to dramatically increase duties on patented pharmaceutical imports, with potential rates mentioned up to 100%.
"This deal with the United Kingdom strengthens the international landscape for cutting-edge drugs and brings long-overdue equity to American-British pharmaceutical trade," a release declared.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's largest export categories to the America, which is by far the primary market for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products totaling billions to the US. This amount accounted for 17.4% of all goods exports in that span.
"This deal protects jobs, stimulates funding and facilitates the UK to emerge as a global hub for biotech and pharma," a government official commented.
Key British Pledges
The deal includes several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The sum drug companies must refund to the NHS to stay within budget will be restricted at 15%. In the past, rebates were more than 20%.
Broader Context
The pact follows a ongoing tension between the pharmaceutical industry and the British authorities over spending levels and approval rates.
The disagreement were exacerbated by assertions that American consumers were paying significantly more for the identical medicines than consumers in the other developed nations.
Recently, several significant manufacturing plans in the UK have been delayed or scrapped, while substantial funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.
